- Home
- STHO vs CHRS Comparison
STHO vs CHRS Comparison
Compare STHO & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STHO
- CHRS
- Stock Information
- Founded
- STHO N/A
- CHRS 2010
- Country
- STHO United States
- CHRS United States
- Employees
- STHO N/A
- CHRS 177
- Industry
- STHO Real Estate
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STHO Real Estate
- CHRS Health Care
- Exchange
- STHO Nasdaq
- CHRS Nasdaq
- Market Cap
- STHO 113.4M
- CHRS 149.9M
- IPO Year
- STHO N/A
- CHRS 2014
- Fundamental
- Price
- STHO $8.74
- CHRS $1.37
- Analyst Decision
- STHO
- CHRS Strong Buy
- Analyst Count
- STHO 0
- CHRS 4
- Target Price
- STHO N/A
- CHRS $4.51
- AVG Volume (30 Days)
- STHO 50.2K
- CHRS 1.4M
- Earning Date
- STHO 11-04-2025
- CHRS 11-05-2025
- Dividend Yield
- STHO N/A
- CHRS N/A
- EPS Growth
- STHO N/A
- CHRS N/A
- EPS
- STHO N/A
- CHRS 1.55
- Revenue
- STHO $113,989,000.00
- CHRS $272,209,000.00
- Revenue This Year
- STHO N/A
- CHRS N/A
- Revenue Next Year
- STHO N/A
- CHRS $126.00
- P/E Ratio
- STHO N/A
- CHRS $0.88
- Revenue Growth
- STHO N/A
- CHRS 52.33
- 52 Week Low
- STHO $6.06
- CHRS $0.66
- 52 Week High
- STHO $14.50
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- STHO 68.36
- CHRS 73.83
- Support Level
- STHO $8.39
- CHRS $1.26
- Resistance Level
- STHO $8.77
- CHRS $1.39
- Average True Range (ATR)
- STHO 0.25
- CHRS 0.08
- MACD
- STHO 0.03
- CHRS 0.02
- Stochastic Oscillator
- STHO 85.53
- CHRS 94.10
About STHO Star Holdings Shares of Beneficial Interest
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. The Company operates its business through one reportable and operating segment that focuses on realizing value for shareholders by generating cash flows through active asset management and sales of its existing loans, operating properties and land and development properties.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.